RE:RE:RE:G12C/G12V KRAS mutation in PC & CRC patients respond to PelaOctober 08, 2021 - Mirati/Sanofi announcement to collaborate.
Mirati Therapeutics, the little biotech is teaming up with French pharma giant Sanofi, wedding its experimental KRAS inhibitor adagrasib with Sanofi’s investigational SHP2 inhibitor SAR442720 in patients who have already had some treatment in KRAS G12C-positive non-small lung cell cancers (NSCLCs) .
SHP2, the tyrosine phosphatase encoded by oncogene PTPN11, drives a subset of cancers and has a role in the RTK-RAS-MAPK cascade and other pathways that are dysregulated in tumors.
Knowledge of these links led Revolution to work on inhibitors that block these signaling cascades, slowing tumor growth. The inhibitors may be effective in cancers of the lung, colon and skin with mutations in KRAS, NF1 or BRAF.
SHP2 is upstream of KRAS and referees cellular signaling through the RAS/MAP kinase pathway; it's often overactive in various types of cancer. KRAS G12C inhibition and SHP2 inhibition have “complementary mechanisms of action and have demonstrated additive anti-tumor activity in preclinical models,” the pair said in a statement, and the companies will now take this idea into the clinic to see whether it pans out.
Under the deal, Sanofi is responsible for sponsoring and operating the phase 1/2 study, and, jointly with Mirati, “will oversee and share costs of the study,” though no other financial terms were disclosed.
https://www.fiercebiotech.com/biotech/mirati-sanofi-join-forces-lung-cancer-a-kras-shp2-combo-approach